Trial Profile
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Semaxanib (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 03 Jul 2018 New trial record